会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • MATRIX METALLOPROTEINASSES AND USES THEREOF
    • MATRIX METALLOPROTENESESES及其用途
    • US20160053250A1
    • 2016-02-25
    • US14782118
    • 2014-04-04
    • Claudia ZYLBERBERGGregg B. FIELDS
    • Claudia ZYLBERBERGGregg B. FIELDS
    • C12N9/64A61K38/48
    • C12N9/6491A61K38/4886C12N9/6416C12Y304/24C12Y304/24007C12Y304/24017C12Y304/24024C12Y304/24034C12Y304/24035C12Y304/24065
    • Matrix metalloproteinases (MMPs) compositions, inactive forms of MMPs (e.g. proMMPs), fragments, mutants, variants or combinations thereof. A pharmaceutical composition comprises one or more of the above in a pharmaceutical carrier. A composition comprises at least one of: a matrix metalloproteinase (MMP), an inactive MMP or a proenzyme (proMMP) thereof, wherein the matrix metalloproteinase (MMPs), inactive MMPs or proMMPs thereof, comprise: MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-11, MMP-12, MMP-13.MMP-14, MMP-15, MMP-16, MMP-17, MMP-18, MMP-19, MMP-20, MMP-21, MMP-23A, MMP-23B, MMP-24, MMP-25, MMP-26, MMP-27, MMP-28, active fragments, mutants, variants or any combinations thereof. The uses include isolation of cells, in particular stem cells, from tissues, dissociation of tissues, proteins and treatment of a variety of conditions.
    • 基质金属蛋白酶(MMPs)组合物,MMPs的无活性形式(例如proMMP),片段,突变体,变体或其组合。 药物组合物在药物载体中包含上述一种或多种。 组合物包含以下中的至少一种:基质金属蛋白酶(MMP),非活性MMP或其酶原(proMMP),其中所述基质金属蛋白酶(MMP),其无活性的MMP或其proMMP包含:MMP-1,MMP-2, MMP-3,MMP-7,MMP-8,MMP-9,MMP-10,MMP-11,MMP-12,MMP-13MMP-14,MMP-15,MMP-16, 18,MMP-19,MMP-20,MMP-21,MMP-23A,MMP-23B,MMP-24,MMP-25,MMP-26,MMP-27,MMP-28,活性片段,突变体, 其组合。 用途包括从组织中分离细胞,特别是干细胞,分解组织,蛋白质以及各种条件的治疗。
    • 5. 发明授权
    • Solid-phase method for attaching a biomolecule to a substrate surface
with a photoreactive crosslinking agent
    • 用光反应性交联剂将生物分子附着到基材表面的固相方法
    • US5853744A
    • 1998-12-29
    • US699965
    • 1996-08-20
    • Daniel L. MooradianGregg B. Fields
    • Daniel L. MooradianGregg B. Fields
    • A61L27/34A61L27/50C12N5/00A61F2/06C07K17/06C12N11/06
    • C12N5/0068A61L27/34A61L27/507C12N2533/30C12N2533/50Y10S530/81Y10S530/812Y10S530/815Y10S530/816
    • A method for making a medical device having a biomolecule immobilized on a substrate surface is provided. The method includes: providing an immobilized biomolecule comprising a biomolecule covalently attached to a support material; attaching a photoreactive crosslinking agent to the immobilized biomolecule to form a photoreactive analog of the biomolecule; and removing the photoreactive analog of the biomolecule from the support material. The photoreactive analog of the biomolecule can then be attached to a substrate surface, such as a biomaterial that forms part of a medical device. The immobilized biomolecule may contain a peptide having an N.sup..alpha. -terminus. The photoreactive crosslinking agent is attached to the peptide at the N.sup..alpha. -terminus to form the photoreactive analog of the biomolecule. The peptide can be an adhesion peptide containing the sequence Trp-Gln-Pro-Pro-Arg-Ala-Arg-Ile. Attachment of the peptide to a substrate surface promotes cell adhesion to the surface. The photoreactive crosslinking agent can be heterobifunctional or contain two photoreactive groups. The photoreactive analog of the biomolecule is attached to the substrate surface by activating a photoreactive group of the analog such as by exposing the analog to UV radiation.
    • 提供一种制造具有固定在基板表面上的生物分子的医疗装置的方法。 该方法包括:提供固定化的生物分子,其包含共价连接到载体材料上的生物分子; 将光反应性交联剂附着到固定化的生物分子上以形成生物分子的光反应性类似物; 并从载体材料中除去生物分子的光反应性类似物。 然后可以将生物分子的光反应性类似物连接到基底表面,例如形成医疗装置的一部分的生物材料。 固定化的生物分子可以含有具有Nα末端的肽。 光反应性交联剂以Nα末端连接到肽上以形成生物分子的光反应性类似物。 肽可以是含有序列Trp-Gln-Pro-Pro-Arg-Ala-Arg-Ile的粘附肽。 将肽附着到基底表面促进细胞对表面的粘附。 光反应性交联剂可以是异双官能的或含有两个光反应性基团。 生物分子的光反应性类似物通过激活类似物的光反应性基团(例如通过将类似物暴露于紫外线辐射)而附着到基底表面。
    • 7. 发明授权
    • Discriminatory substrates for MMP hydrolysis
    • MMP水解的歧视底物
    • US5770691A
    • 1998-06-23
    • US464337
    • 1995-06-05
    • Gregg B. FieldsHideaki Nagase
    • Gregg B. FieldsHideaki Nagase
    • C07K7/06C12Q1/37A61K38/04A61K7/16A61K38/00
    • C07K7/06C12Q1/37C12Q2337/22G01N2333/96486
    • A method of screening a sample for the presence of a matrix metalloproteinase employing discriminatory peptide substrates is provided. The method involves providing a peptide substrate of 6-14 amino acid residues containing at least one matrix metalloproteinase cleavage site. The peptide substrate contains Mca as a fluorogenic group and Lys(Dnp) as a quenching group separated by at least four amino acid residues, wherein the peptide substrate is specific for the matrix metalloproteinase of interest. The peptide substrate is combined with a sample containing at least one matrix metalloproteinase to form a mixture. The fluorescence of the mixture is monitored to determine if the matrix metalloproteinase of interest is present.
    • 提供了使用鉴别性肽底物筛选样品存在基质金属蛋白酶的方法。 该方法包括提供含有至少一个基质金属蛋白酶切割位点的6-14个氨基酸残基的肽底物。 肽底物含有作为荧光基团的Mca,并且由至少四个氨基酸残基分开的作为猝灭基团的Lys(Dnp),其中肽底物对感兴趣的基质金属蛋白酶是特异性的。 将肽底物与含有至少一种基质金属蛋白酶的样品组合以形成混合物。 监测混合物的荧光以确定感兴趣的基质金属蛋白酶是否存在。